Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Pharmaforce ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 3.7% 3.7%   Bankruptcy risk   1.6% 1.2% 1.2% 1.2% 1.9% 1.6% 9.4% 9.4%   Credit score (0-100)   76 83 81 82 69 74 26 26   Credit rating   A A A A A A BB BB   Credit limit (kDKK)   6.9 91.4 84.2 126.6 0.8 11.5 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   3,685 4,305 4,305 4,202 3,640 3,682 0.0 0.0   EBITDA   1,670 1,416 1,416 465 425 344 0.0 0.0   EBIT   1,670 1,416 1,416 465 425 344 0.0 0.0   Pre-tax profit (PTP)   1,525.2 1,398.7 1,398.7 478.3 370.4 345.0 0.0 0.0   Net earnings   1,177.2 1,080.8 1,080.8 367.5 282.7 262.2 0.0 0.0   Pre-tax profit without non-rec. items   1,525 1,399 1,399 478 370 345 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   2,164 2,508 2,508 2,875 2,858 2,920 2,295 2,295   Interest-bearing liabilities   9.4 343 343 1,979 172 27.9 0.0 0.0   Balance sheet total (assets)   4,866 6,139 6,139 6,776 5,635 4,787 2,295 2,295   Net Debt   -1,335 -207 -207 980 -647 -1,498 -2,295 -2,295     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   3,685 4,305 4,305 4,202 3,640 3,682 0.0 0.0   Gross profit growth   62.8% 16.8% 0.0% -2.4% -13.4% 1.2% -100.0% 0.0%   Employees   3 5 5 5 5 5 0 0   Employee growth %   50.0% 66.7% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   4,866 6,139 6,139 6,776 5,635 4,787 2,295 2,295   Balance sheet change%   47.9% 26.2% 0.0% 10.4% -16.8% -15.1% -52.0% 0.0%   Added value   1,669.8 1,415.7 1,415.7 465.5 424.6 344.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   45.3% 32.9% 32.9% 11.1% 11.7% 9.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   40.9% 26.3% 23.5% 8.2% 6.9% 7.4% 0.0% 0.0%   ROI %   94.3% 57.5% 50.7% 13.8% 10.9% 12.9% 0.0% 0.0%   ROE %   74.7% 46.3% 43.1% 13.7% 9.9% 9.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   47.5% 42.4% 42.4% 42.4% 50.7% 61.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -80.0% -14.6% -14.6% 210.5% -152.4% -435.1% 0.0% 0.0%   Gearing %   0.4% 13.7% 13.7% 68.8% 6.0% 1.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   73.7% 25.9% 13.3% 4.5% 5.3% 41.9% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.2 1.4 1.4 1.4 1.3 1.5 0.0 0.0   Current Ratio   1.8 1.8 1.8 1.8 2.0 2.6 0.0 0.0   Cash and cash equivalent   1,344.5 550.4 550.4 999.4 818.9 1,525.8 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   2,082.5 2,730.4 2,730.4 2,938.4 2,776.0 2,919.2 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   557 283 283 93 85 69 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   557 283 283 93 85 69 0 0   EBIT / employee   557 283 283 93 85 69 0 0   Net earnings / employee   392 216 216 73 57 52 0 0